Last reviewed · How we verify
Argipressin
At a glance
| Generic name | Argipressin |
|---|---|
| Also known as | Arg |
| Sponsor | Kristina Svennerholm |
| Target | Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hereditary factor VIII deficiency disease
- Nocturnal enuresis
- Partial Central Diabetes Insipidus
- von Willebrand disorder
Common side effects
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair (PHASE2)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
- Tranexamic Acid vs Vasopressin in Placenta Previa Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |